Xeligekimab in Plaque Psoriasis: Regional and DLQI Gains
Key Takeaways
- In Chinese adults with moderate-to-severe plaque psoriasis in a phase 3 trial, xeligekimab was associated with high week-12 ideal and acceptable target attainment that remained high through week 52.
- Xeligekimab produced markedly greater week-4 PASI component improvement than placebo, with deeper improvement by week 12.
- Patient-reported burden improved quickly, with low-impact DLQI rates above 90% across measured domains by week 12 and early improvement in pruritus.
- Sustained remission took months to emerge and was observed in about half of xeligekimab-treated patients by weeks 52 to 60.
In a post hoc analysis of a phase 3 randomized, double-blind, placebo-controlled, multicenter trial, investigators evaluated 420 Chinese adults aged 18 to 70 years who had chronic plaque psoriasis for at least 6 months and inadequate response to conventional therapies. Entry criteria included a baseline Psoriasis Area and Severity Index (PASI) of at least 12, Physician’s Global Assessment (PGA) of at least 3, and body surface area (BSA) involvement of at least 10%.
Patients were randomized 2:1 to subcutaneous xeligekimab 200 mg every 2 weeks or placebo for 12 weeks, then received open-label xeligekimab every 4 weeks through week 52 with safety follow-up through week 60. Outcomes included PASI components, regional responses, treatment targets, sustained remission, Dermatology Life Quality Index (DLQI) domains, and pruritus on a Numerical Rating Scale (NRS).
By week 4, PASI component reductions with xeligekimab were −60.1% versus −7.7% for induration, −61.9% versus −6.1% for scaling, and −50.3% versus −5.3% for erythema, all P<0.001. Those reductions deepened further by week 12, showing early separation from placebo across the plaque features used in routine skin assessment.
At week 12, 86.6% met the study's defined ideal target and 94.9% met the defined acceptable target, versus 4.6% and 9.9% with placebo; these targets were met by achieving any one of several criteria (eg, PASI, absolute PASI, BSA, or PGA thresholds). Sustained remission had a median time of 48 weeks, with cumulative rates of 50.1% at week 52 and 54.1% at week 60. Head lesions responded fastest, lower limbs lagged early before later catch-up, low-impact DLQI rates exceeded 90% across measured domains by week 12, and placebo-switched patients reached comparable skin, regional, and patient-reported responses during later follow-up.
The authors described the analysis as post hoc and exploratory and noted residual multiple-comparison risk despite Benjamini-Hochberg adjustment. They also noted the entirely Chinese study population, descriptive open-label follow-up after week 12, the 60-week observation window, and the absence of safety, contraindication, or patient-selection guidance.
Within this trial dataset, the authors interpreted xeligekimab as being associated with rapid, deep, and sustained multidimensional improvement across skin signs, regional clearance patterns, treatment targets, and patient-reported burden in moderate-to-severe plaque psoriasis.
Clinician Questions
Which patients with plaque psoriasis were represented in the xeligekimab phase 3 trial?
The phase 3 trial enrolled Chinese adults aged 18 to 70 years with chronic plaque psoriasis for at least 6 months, baseline PASI of at least 12, PGA of at least 3, BSA of at least 10%, and inadequate response to conventional therapies; notably, 87.1% of participants were biologic-naive. These findings are therefore most applicable to patients with similar baseline severity and treatment history, and direct extension beyond similar populations is limited.
How was sustained remission defined for xeligekimab-treated plaque psoriasis in this analysis?
Sustained remission was defined as continuous BSA of 0% or PGA of 0 for at least 24 weeks. Investigators adapted a National Psoriasis Foundation framework because the trial used PGA rather than an Investigator’s Global Assessment.
What happened after placebo-treated patients crossed over to xeligekimab in plaque psoriasis?
After crossover at week 12, placebo-switched patients achieved comparable PASI component improvement by week 24 and comparable regional and patient-reported responses during weeks 24 to 52. The later-response pattern suggested that delayed initiation was followed by gains across both clinician-assessed and patient-reported measures.
What features of the xeligekimab analysis most limit generalizability?
The main limits on generalizability were the post hoc exploratory design, residual multiple-comparison risk despite Benjamini-Hochberg adjustment, the entirely Chinese study population, descriptive open-label follow-up after week 12, the lack of safety analysis in this efficacy-focused report, and unresolved durability beyond 60 weeks.